Dr. Nanda Rajneesh, General and Laparoscopic Surgeon, FACRSI, FICS, MRCS, FAMS, Apollo Spectra Hospital, Bangalore, explains that medical researchers have developed new ways of fighting obesity at a time when the need to reduce obesity rates is increasing. Weight management solutions of today reflect medical developments that work against obesity. The article discusses current medical discoveries that present new possibilities for dealing with one of our generation's most critical health issues.
GLP-1 Receptor Agonists (e.g., Semaglutide, Tirzepatide)
Obesity medicine practices have undergone substantial changes because of new therapeutic agent innovations that have appeared in the last few years. GLP-1 RAs represent new obesity medications that include semaglutide together with the older medication liraglutide and the recently authorised tirzepatide, a dual GLP-1/GIP RAs agonist. The drugs successfully decrease body weight because this method produces effective results in obesity treatment. The medications aid weight reduction while improving blood lipid status and blood sugar levels, together with the belly obesity assessments.
Dual and Triple Hormone therapies (e.g., Amycretin)
The compound amycretin functions as both a GLP-1 receptor activator and an amylin receptor activator. The two-step action mode of this molecule directs its effects to appetite controls and metabolic processes to provide potential weight management benefits. The pharmaceutical company Novo Nordisk conducts clinical trials for amylincretin, which exists as an oral and subcutaneous medication.
Oral GLP-1 Receptor Agonists (e.g., Aleniglipron)
The GLP-1 receptor agonist aleniglipron (GSBR-1290) comes in an oral form from Structure Therapeutics. The Phase 2a obesity study showed that aleniglipron produced meaningful and statistically significant weight reduction while maintaining safe operation and tolerability patterns.
Amylin Analogue Therapies
The hormone amylin controls both appetite and blood sugar regulation functions. The licensing agreement between AbbVie and Gubra involves GUB014295, which targets amylin to treat obesity. Initial Phase 1 testing verified that patients lost an average of 3 percent of their body weight.
Bariatric Surgery Innovations
Bariatric surgery stands as a highly efficient medical intervention for people who suffer from serious obesity. Patients sometimes develop post-bariatric hypoglycemia (PBH), which produces intense hypoglycemic episodes, likely after this medical procedure. The advancement of medical research aims to meet this unmet medical need, and Amylyx Pharmaceuticals, among other companies, contributes to this effort through therapeutic development.
Gut-Brain Axis Modulation
Experts state that signalling modification between the brain and gut shows potential for regulating metabolic function and hunger-related responses. Research has found that a newly developed compound has demonstrated promising results regarding weight loss and appetite reduction in laboratory animals by activating GLP-1 and leptin receptors simultaneously.
Conclusion: The Future of Obesity Treatment
Medical research, along with gene studies and pharmaceutical progress, is speeding up obesity treatment approaches. Science continues to advance toward success but requires a combination of medical developments, healthier life choices, and improved policy and healthcare support. The big question remains: Are we on the brink of curing obesity for good? The answer may be closer than we think.
About The Author
.jpeg)
Comment List